Evaluation of Dexterity in Insulin-Treated Patients with Type 1 and Type 2 Diabetes Mellitus

Pfützner, J; Hellhammer, Juliane; Musholt, Petra B.; Pfützner, A.; Böhnke, Jan R.; Hero, Torsten; Amann-Zalán, Ildikó; Ganz, Manfred; Forst, Thomas

doi:10.1177/193229681100500122

Cited by 44 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pfutzner et al 6, 7. also reported that patients with diabetes mellitus showed significant dexterity deficits, which might result in difficulties when carrying out therapeutic protocols in their daily routines (e.g., monitoring blood glucose or injecting insulin).…”

Section: Discussionmentioning

confidence: 99%

Do we underestimate influences of diabetic mononeuropathy or polyneuropathy on hand functional performance and life quality?

Yang

Hsu

et al. 2017

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionThe purpose of the present study was to identify whether there are differences in hand dexterity, hand functional performance and quality of life between diabetes patients with mononeuropathy and polyneuropathy of their hands to further present the importance regarding the impacts of diabetic neuropathic deficits on patients’ functional capacity.Materials and MethodsThe neurological deficits of 127 patients with type 2 diabetes were examined by electrophysiological tests for the median and ulnar nerves, and were stratified into the diabetic mononeuropathy, diabetic polyneuropathy and non‐diabetic neuropathy groups by sensory amplitude of these nerves. The Purdue pegboard test, Michigan Hand Outcomes Questionnaire, and Diabetes‐39 were carried out to understand patients’ hand dexterity, functional hand performance and quality of life, respectively.ResultsThe results showed significant differences in all subtests of the Purdue pegboard test among the three groups. Furthermore, aesthetics, patient's satisfaction of the Michigan Hand Outcomes Questionnaire and diabetes control, sexual functioning, energy, and mobility of the Diabetes‐39 also showed significant differences among the three groups.ConclusionsThe present study shows the patients with polyneuropathy suffer from more negative impacts on hand functional performance and quality of life than those with mononeuropathy and without neuropathy. These findings might assist both patients and clinicians in better realizing the impacts of neuropathic hands, and planning suitable strategies of intervention or health education to prevent declines in hand functions.

show abstract

Section: Discussionmentioning

confidence: 99%

Do we underestimate influences of diabetic mononeuropathy or polyneuropathy on hand functional performance and life quality?

Yang

Hsu

et al. 2017

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…Studies that include participants with impaired vision and reduced manual dexterity are limited, but recent research with insulin pen devices showed that visual impairments and reduced manual dexterity in patients with T2DM can influence patient preference. 24 Pen devices that can be used with accuracy are important tools that contribute to safety in diabetes treatment. In this study, participants made fewer errors with the lixisenatide pen device than with the other 2 pen devices, with significantly higher successful performance versus the exenatide pen (P = .001).…”

Section: Discussionmentioning

confidence: 99%

“…23 Reduced manual dexterity, such as limited joint mobility syndrome, is often seen in these patients, and may limit finger or hand strength and the ability to inject medication without assistance. 19,[24][25][26] In such patients, the ease with which a pen device can be used without error is of particular importance. In addition, many patients with diabetes are older and may require more time to learn the various functions of a pen device, and ease of use is therefore also important in this population.…”

mentioning

confidence: 99%

Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices

Stauder

Enginee

Elton

et al. 2014

J Diabetes Sci Technol

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) receptor agonists are a relatively new therapeutic option for the treatment of type 2 diabetes mellitus (T2DM). These agents are generally well tolerated and provide glycemic control and other clinical benefits. 1,2 Aside from their efficacy in reducing glycated hemoglobin via effects on both fasting plasma glucose and postprandial plasma glucose, GLP-1 receptor agonists allow patients to achieve glycemic targets, with beneficial effects on weight being reported. 1,3-6 One of the key benefits of GLP-1 receptor agonists is that they stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner, and therefore carry a limited risk of hypoglycemia. 3,7 The GLP-1 receptor agonists currently available are exenatide (Byetta ® , Bristol-Myers Squibb/AstraZeneca), administered as a twice-daily injection; 8 liraglutide (Victoza ® , Novo Nordisk), administered as a once-daily injection; 9 exenatide (Bydureon ® , Bristol-Myers Squibb/AstraZeneca), administered as a once-weekly injection; and lixisenatide (Lyxumia ® , Sanofi-Aventis), a once-daily prandial GLP-1 receptor agonist. 10 Twice-daily exenatide as well as oncedaily liraglutide and once-daily lixisenatide are available as ready-to-use prefilled pen devices for subcutaneous injection. Exenatide is available in 2 different fixed-dose 511733D STXXX10.

show abstract

“…Insulin dose adjustment and administration can be further complicated by physical limitations such as visual impairment or manual dexterity. 18 For people living with diabetes treated with insulin, adherence to blood glucose testing and medication also appears to be influenced by regimen complexity. This includes the number of insulin injections, individual perception of side effects, the intrusion of medication on personal aspects of daily living cost, and concerns about excessive weight gain.…”

Section: Inadequate Insulin Administrationmentioning

confidence: 99%

Actionable Self-Monitoring of Blood Glucose: Redefining the Role for Patients Using Multiple Daily Injection Therapy

Kerr

Messing

Resch

2011

J Diabetes Sci Technol

View full text Add to dashboard Cite

Abbreviations: (MDI) multiple daily injection, (SMBG) Journal of Diabetes Science and TechnologyVolume 5, Issue 6, November 2011 © Diabetes Technology Society Abstract Self-monitoring of blood glucose (SMBG) values is an accepted requirement for patients with diabetes using multiple daily injections of insulin. Nevertheless, for many patients, the full value of SMBG has yet to be realized due to a number of factors that contribute to patients not taking appropriate action based on the achieved result. The reasons for this are complex but are related to the burden imposed by performing the tests, the need for complex numerical calculations, and the demand for undertaking this activity multiple times each day.In the near future, SMBG devices are likely to include technological innovations that are aimed at overcoming these barriers, offering "actionable" SMBG for patients using insulin. These innovations should include technologies that will allow customization and individualization based upon specific therapy regimens.

show abstract

Evaluation of Dexterity in Insulin-Treated Patients with Type 1 and Type 2 Diabetes Mellitus

Cited by 44 publications

References 16 publications

Do we underestimate influences of diabetic mononeuropathy or polyneuropathy on hand functional performance and life quality?

Do we underestimate influences of diabetic mononeuropathy or polyneuropathy on hand functional performance and life quality?

Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices

Actionable Self-Monitoring of Blood Glucose: Redefining the Role for Patients Using Multiple Daily Injection Therapy

Contact Info

Product

Resources

About